Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial We previously reported initial results of the ...
Prostate cancer management has long been challenged by the limitations of traditional screening tools like PSA testing, which contribute to significant rates of overdiagnosis and overtreatment. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results